

# The effect of local anaesthetic and adrenaline injection on pain relief after a total hip replacement

<b>Submission date</b> 09/02/2026	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 14/04/2026	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Protocol
<b>Last Edited</b> 14/04/2026	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Pain relief medications after a hip replacement can come in different modalities. A particular technique used by surgeons is the use of an injection used during the surgery around the hip joint. This injection is a combination of local anaesthetic with adrenaline. It's use is well-established in total knee replacement. However, it's role in total hip arthroplasty is not fully understood. This leads to discrepancies in practice between surgeons. To date there have been low quality, small, randomised control trials with conflicting results. Additionally, there has been no established protocol described in these studies for the delivery of the peri-articular injection.

This study will aim to determine the effects of the injection on post relief after a total hip replacement. The injection will be given according to an agreed protocol amongst the surgeons. Pain control will be measured by asking patients questions from the International Pain Outcomes questionnaire. This will be recorded at 2 different time-points; 24 hours and 48 hours after the operation. Additionally, opioid consumption throughout the patients stay in hospital will also be assessed (measuring Morphine Milligram Equivalents) to determine additionally pain relief requirements.

### Who can participate?

Patient over 18 years old with osteoarthritis who have been scheduled for total hip arthroplasty. Patients under 18 years old, patients with cognitive impairment, previous diagnosis of a pain syndrome, patient's undergoing bilateral total hip arthroplasty or revision total hip arthroplasty will not be able to take part.

### What does the study involve?

Patients undergoing total hip arthroplasty under spinal anaesthetic will be randomised into 2 groups; A & B. Group A will receive a periarticular injection which will be administered to the agreed protocol. Group B will not receive the periarticular injection. Patients will be consented on the morning of their surgery and will be provided with a patient information leaflet. Only

surgeons who perform posterior approach total hip arthroplasty will be included to minimise confounding factors between patients. Additionally, patients will all be given the standard post-operative analgesia and physio regime.

What are the possible benefits and risks of participating?

The use of local anaesthetic can have rare side effects such as nausea, vomiting, dizziness, headache.

Where is the study run from?

The study is being carried out at the National Orthopaedic Hospital Cappagh in Dublin (Ireland)

When is the study starting and how long is it expected to run for?

October 2025 to April 2026.

Who is funding the study?

The study is funded by Consultant Innovation Funding from the Health Service Executive (Ireland)

Who is the main contact?

Mr James Cashman, Consultant Orthopaedic Surgeon at the National Orthopaedic Hospital Cappagh, james.cashman@gmail.com

## Contact information

### Type(s)

Principal investigator

### Contact name

Mr James Cashman

### Contact details

National Orthopaedic Hospital Cappagh, Cappagh Rd, Finglas

Dublin

Ireland

D11 EV29

+353 1 814 0400

james.cashman@gmail.com

### Type(s)

Scientific, Public

### Contact name

Mr Ross Condell

### ORCID ID

<https://orcid.org/0000-0002-9136-0399>

### Contact details

National Orthopaedic Hospital Cappagh, Cappagh Rd, Finglas

Dublin

Ireland

D11EV29  
+353 1 814 0400  
rosscondell@rcsi.com

## Additional identifiers

## Study information

### Scientific Title

PANTHER trial: Efficacy of peri-articular injection in total hip replacement for pain relief. a single-centre, double-blinded randomised controlled trial

### Acronym

PANTHER

### Study objectives

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 24/09/2025, National Orthopaedic Hospital Cappagh Research Ethics Committee (National Orthopaedic Hospital Cappagh, Cappagh Rd, Finglas, Dublin, D11EV29, Ireland; +353 1 814 0400; mary.byrne@nohc.ie), ref: NOHC-2025-ETH-MB-CEO-383

### Primary study design

Interventional

### Allocation

Randomized controlled trial

### Masking

Blinded (masking used)

### Control

Placebo

### Assignment

Parallel

### Purpose

Treatment

### Study type(s)

### Health condition(s) or problem(s) studied

Pain relief for patients undergoing a total hip replacement for osteoarthritis.

### Interventions

Patients undergoing total hip arthroplasty under spinal anaesthetic were recruited for the study and prospectively randomised into groups; A & B. Treatment allocations were randomised using sealed opaque envelopes. Group A will receive the periarticular injection which will be administered to the agreed protocol by the surgeon during the procedure. The protocol for administering the periarticular injection is as follows; 50ml anterior to the acetabular cup, 50ml to the psoas compartment and 50ml to the subcutaneous tissues. Group B will not receive the periarticular injection. Patients will be consented on the morning of their surgery and will be provided with a patient information leaflet. Only surgeons who perform posterior approach total hip arthroplasty will be included to minimise confounding factors between patients. Additionally, both groups of patients will all be given the standard post-operative analgesia and physio regime. Both groups of patients will be followed-up until discharge from hospital.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Chirocaine 5mg/ml solution for injection/concentrate for solution for infusion. Chirocaine 7.5mg/ml solution for injection/concentrate for solution for infusion. 0.9% w/v Sodium Chloride Injection BP. Adrenaline (Epinephrine) 1:1,000 Solution for Injection.

### **Primary outcome(s)**

1. International Pain Outcomes questionnaire measured using numeric pain rating scale (0-10, 0-100%) and binary Yes/No answers at 24 hours and 48 hours post-operatively
2. Opioid Consumption measured using milligrams morphine equivalents from patient records at time of discharge

### **Key secondary outcome(s)**

1. Length of stay measured using number of days as in-patient from patient records at time of discharge
2. Time to physio discharge measured using number of days from patient records at time of physio discharge
3. Blood loss measured using millilitres of blood loss from patient records at time of operation

### **Completion date**

01/05/2026

## **Eligibility**

### **Key inclusion criteria**

Patient over 18 years old with osteoarthritis who have been scheduled for total hip arthroplasty

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Patients <18 years old
2. Patients with cognitive impairment
3. Previous diagnosis of a pain syndrome
4. Patient's undergoing bilateral total hip arthroplasty or revision total hip arthroplasty

**Date of first enrolment**

01/10/2025

**Date of final enrolment**

01/04/2026

## **Locations**

**Countries of recruitment**

Ireland

**Study participating centre**

**National Orthopaedic Hospital Cappagh**

National Orthopaedic Hospital Cappagh, Cappagh Rd, Finglas, D11 EV29

Ireland

## **Sponsor information**

**Organisation**

Health Service Executive

**ROR**

<https://ror.org/04zke5364>

# Funder(s)

## Funder type

### Funder Name

Health Service Executive

### Alternative Name(s)

Ireland's Health Services, Feidhmeannacht na Seirbhíse Sláinte, HSE

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

Ireland

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Other files</a>	Consent form		09/02/2026	No	No
<a href="#">Participant information sheet</a>			09/02/2026	No	Yes